晚期或复发性宫颈癌的治疗

doi:10.3760/cma.j.issn.1673-422X.2018.01.010

摘要/Abstract

摘要： 晚期或复发性宫颈癌的治疗是临床难点，多数患者已经失去手术或放疗的机会，以化疗为主的姑息性治疗是主要治疗手段。近年来，分子靶向及免疫治疗的深入研究为晚期或复发性宫颈癌患者提供了新的治疗策略，改善了患者的疗效及生命质量。

Abstract: The treatment of advanced or recurrent cervical cancer is difficult in clinic. Most of the patients have lost the opportunities for surgery or radiotherapy. Palliative treatment with chemotherapy is the main treatment. In recent years, the intensive studies on molecular targeted therapy and immunotherapy have provided a new treatment strategy for patients with advanced or recurrent cervical cancer, improving the efficacy and quality of life of patients.

Key words: Uterine cervical neoplasms, Drug therapy, Immunotherapy, Molecular targeted therapy

李丹，楼寒梅. 晚期或复发性宫颈癌的治疗[J]. 国际肿瘤学杂志, 2018, 45(1): 44-.

Li Dan*, Lou Hanmei. Treatment of advanced or recurrent cervical cancer[J]. Journal of International Oncology, 2018, 45(1): 44-.

参考文献

［1］ Pfaendler KS, Tewari KS. Changing paradigms in the systemic treatment of advanced cervical cancer［J］. Am J Obstet Gynecol, 2016, 214(1): 2230. DOI: 10.1016/j.ajog.2015.07.022. ［2］ Thigpen T. The role of chemotherapy in the management of carcinoma of the cervix［J］. Cancer J, 2003, 9(5): 425432. ［3］ Moore DH, Blessing JA, McQuellon RP, et al. Phase Ⅲ study of cisplatin with or without paclitaxel in stage ⅣB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study［J］. J Clin Oncol, 2004, 22(15): 31133119. DOI: 10.1200/JCO.2004.04.170. ［4］ Long HJ 3rd, Bundy BN, Grendys EC Jr, et al. Randomized phase Ⅲ trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oneology Group Study［J］. J Clin Oncol, 2005, 23(21): 46264633. DOI: 10.1200/JCO.2005.10.021. ［5］ Monk BJ, Sill MW, McMeekin DS, et al. Phase Ⅲ trial of four cisplatincontaining doublet combinations in stage ⅣB, recurrent or persistent cervical carcinoma: a Gynecologic Oncology Group study［J］. J Clin Oncol, 2009, 27(28): 46494655. DOI: 10.1200/JCO.2009.21.8909. ［6］ Matoda M, Tanigawa T, Omatsu K, et al. Platinumfree interval in secondline chemotherapy for recurrent cervical cancer［J］. Int J Gynecol Cancer, 2013(23): 16701674. DOI: 10.1097/IGC.0b013e3182a80a07. ［7］ Nishio S, Kitagawa R, Shibata T, et al. Prognostic factors from a randomized phase Ⅲ trial of Paclitaxel and carboplatin versus paclitaxel and cisplatin in metastaticor recurrent cervical cancer: Japan Clinical Oncology Group (JCOG) trial: JCOG0505S1［J］. Cancer Chemother Pharmacol, 2016, 78(4): 785790. DOI: 10.1007/s0028001631334. ［8］ Tanioka M, Katsumata N, Yonemori K, et al. Second platinum therapy in patients with uterine cervical cancer previously treated with platinum chemotherapy［J］. Cancer Chemother Pharmacol, 2011, 68(2): 337342. DOI: 10.1007/s0028001014947. ［9］ Kitagawa R, Katsumata N, Shibata T, et al. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the openlabel randomized phase Ⅲ trial (JCOG0505)［J］. J Clin Oncol, 2015, 33(19): 21292135. DOI: 10.1200/JCO.2014.58.4391. ［10］ Lorusso D, Ferrandin G, Pignata S, et al. Evaluation of pemetrexed (Alimta, LY231514) as secondline chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group［J］. Ann Oncol, 2010, 21(1): 6166. DOI: 10.1093/annonc/mdp266. ［11］ Miller DS, Blessing JA, Ramondetta LM, et al. Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: a limited access phase Ⅱ trial of the gynecologic oncology group［J］. J Clin Oncol, 2014, 32(25): 27442749. DOI: 10.1200/JCO.2013.54.7448. ［12］ Alberts DS, Blessing JA, Landrum LM, et al. Phase Ⅱ trial of nabpaclitaxel in the treatment of recurrent or persistent advanced cervix cancer: a gynecologic oncology group study［J］. Gynecol Oncol, 2012, 127(3): 451455. DOI: 10.1016/j.ygyno.2012.09.008. ［13］ Yamamoto K, Izumi R, Hasegawa K, et al. Adjuvant oral 5fluorouracil for cervical cancer: Japanese Gynecologic Oncology Group report［J］. Int J Oncol, 2004, 24(5): 11751179. DOI: 10.3892/ ijo.24.5.1175. ［14］ Katsumata N, Hirai Y, Kamiura S, et al. Phase Ⅱ study of S1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer［J］. Ann Oncol, 2011, 22(6): 13531357. DOI: 10.1093/annonc/mdq602. ［15］ Phase Ⅲ study of S1 + cisplatin vs cisplatin in cervical cancer. 2016.NCT00770874［DB/OL］ . https://clinicaltrials.gov. ［16］ Mitsuhashi A, Suzuka K, Yamazawa K, et al. Serum vascular endothelial growth factor (VEGF) and VEGFC levels as tumor markers in patients with cervical carcinoma［J］. Cancer, 2005, 103(4): 724730. DOI: 10.1002/cncr.20819. ［17］ Tewari KS, Sill MW, Long IH, et al. Improved survival with bevacizumab in advanced cervical cancer［J］. N Engl J Med, 2014, 370(8): 734743. DOI: 10.1056/NEJMoa1309748. ［18］ Tewari KS, Sill MW, Penson RT, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, openlabel, phase 3 trial (Gynecologic Oncology Group 240)［J］. Lancet, 2017, 390(10103): 16541663. DOI: 10.1016/S01406736(17)316070. ［19］ Penson RT, Huang HQ, Wenzel LB, et al. Bevacizumab for advanced cervical cancer: patientreported outcomes of a randomised, phase 3 trial (NRG OncologyGynecologic Oncology Group protocol 240)［J］. Lancet Oncol, 2015, 16(3): 301311. DOI: 10.1016/S14702045(15)700045. ［20］ Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase Ⅲ trial［J］. J Clin Oncol, 2010, 28(6): 10611068. DOI: 10.1200/JCO.2009.23.9764. ［21］ Monk BJ, Pandite LN. Survival data from a phase Ⅱ, openlabel study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer［J］. J Clin Oncol, 2011, 29(36): 4845. DOI: 10.1200/JCO.2011.38.8777. ［22］ ConesaZamora P, TorresMoreno D, Isaac MA, et al. Gene amplification and immunohistochemical expression of ERBB2 and EGFR in cervical carcinogenesis. Correlation with cellcycle markers and HPV presence［J］. Exp Mol Pathol, 2013, 95(2): 151155. DOI: 10.1016/j.yexmp.2013.06.011. ［23］ Goncalves A, Fabbro M, Lhommé C, et al. A phase Ⅱ trial to evaluate gefitinib as second or thirdline treatment in patients with recurring locoregionally advanced or metastatic cervical cancer［J］. Gynecol Oncol, 2008, 108(1): 4246. DOI: 10.1016/j.ygyno.2007.07.057. ［24］ Woodworth CD, Diefendorf LP, Jette DF, et al. Inhibition of the epidermal growth factor receptor by erlotinib prevents immortalization of human cervical cells by human papillom avirus type 16［J］. Virology, 2011, 421(1): 1927. DOI: 10.1016/j.virol.2011.09.014. ［25］ Schilder RJ, Sill MW, Lee YC, et al. A phase Ⅱ trial of erlotinib in recurrent squamous cell carcinom a of the cervix: a Gynecologic Oneology Group Study［J］. Gynecol Cancer, 2009, 19(5): 929933. DOI: 10.1111/IGC.0b013e3181a83467. ［26］ NogueiraRodrigues A, Moralez G, Grazziotin R, et al. Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer［J］. Cancer, 2014, 120(8): 11871193. DOI: 10.1002/cncr.28471. ［27］ Kurtz JE, HardyBessard AC, Deslandres M, et al. Cetuximab, topoteean and cisplatin for the treatment of advanced cervical cancer: a phase Ⅱ GINECO trial［J］. Gynecol Oncol, 2009, 113(1): 1620. DOI: 10.1016/j.ygyno.2008.12.040. ［28］ Hertlein L, Lenhard M, Kirschenhofer AA, et al. Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patients［J］. Arch Gynecol Obstet, 2011, 283(1): 109113. DOI: 10.1007/s0040401013891. ［29］ Farley J, Sill MW, Birrer M, et al. Phase Ⅱ study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study［J］. Gynecol Oncol, 2011, 121(2): 303308. DOI: 10.1016/j.ygyno.2011.01.030. ［30］ Cetina L, Crombet T, JiménezLima R, et al. A pilot study of nimotuzumab plus single agent chemotherapy as second or thirdline treatment or more in patients with recurrent, persistent or metastatic cervical cancer［J］. Cancer Biol Ther, 2015, 16(5): 684689. DOI: 10.1080/15384047.2015.1026483. ［31］ Molinolo AA, Marsh C, El Dinali M, et al. mTOR as a molecular target in HPVassociated oral and cervical squamous carcinomas［J］. Clin Cancer Res, 2012, 18(9): 25582568. DOI: 10.1158/10780432.CCR112824. ［32］ Tinker A, Mackay H, Ellard S, et al. Preliminary activity of temsirolimus, an mTOR inhibitor, in patients with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix: a NCICCTG Phase Ⅱ Clinical Trial［J］. Mol Cancer Ther, 2011, 10 Suppl 1: C69. DOI: 10.1158/15357163.TARG11C69. ［33］ Tinker AV, Ellard S, Welch S, et al. Phase Ⅱ study of ternsirolimus (CCI779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical trials Group (NCIC CTG IND 199)［J］. Gynecol Oncol, 2013, 130(2): 269274. DOI: 10.1016/j.ygyno.2013.05.008. ［34］ Thaker PH, Salani R, Brady WE, et al. A phase Ⅰ trial of paclitaxel cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT01281852)［J］. Ann Oncol, 2017, 28(3): 505511. DOI: 10.1093/annonc/mdw635. ［35］ Kunos C, Deng W, Dawson D, et al. A phase ⅠⅡ evaluation of veliparib (NSC737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG Oncology/Gynecologic Oncology Group study［J］. Int J Gynecol Cancer, 2015, 25(3): 484492. DOI: 10.1097/IGC0000000000000380. ［36］ CouzinFrankel J. Breakthrough of the year 2013. Cancer immunotherapy［J］. Science, 2013, 342(6165): 14321433. DOI: 10.1126/science.342.6165.1432. ［37］ Yang W, Lu YP, Yang YZ, et al. Expressions of programmed death (PD)1 and PD1 ligand (PDL1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status［J］. J Obstet Gynaecol Res, 2017, 43(10): 16021612. DOI: 10.1111/jog.13411. ［38］ An investigational immunotherapy study to investigate the safety and effectiveness of nivolumab, and nivolumab combination therapy in virusassociated tumors (CheckMate358). 2015.NCT02488759［DB/OL］ . https://clinicaltrials.gov.

[1]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[3]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[4]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.
[5]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟. 铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[6]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[7]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[8]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[9]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[10]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[11]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[12]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹. 胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[13]	马正红, 姜超. 非小细胞肺癌KRAS^G12C突变的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 95-98.
[14]	金旭东, 陈忠坚, 毛伟敏. MTAP基因在恶性间皮瘤中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 99-104.
[15]	崔腾璐, 吕璐, 孙鹏飞. 放疗联合免疫治疗在头颈部鳞状细胞癌治疗中的应用[J]. 国际肿瘤学杂志, 2023, 50(9): 548-552.